Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LANCL2 | Q9NS86 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23561738 | 0.92 | LANCL2 (0.83) | LANCL2NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL23561755 | 0.91 | LANCL2 (0.70) | LANCL2HTR2ANPC1RAB9AHPGD | |
| SCHEMBL23561754 | 0.90 | LANCL2 (0.73) | LANCL2NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL23561740 | 0.90 | LANCL2 (0.67) | LANCL2HTR2ANPC1RAB9AHPGD | |
| SCHEMBL23561757 | 0.90 | LANCL2 (0.60) | LANCL2HTR2AHPGDALDH1A1KDM4E | |
| SCHEMBL23561758 | 0.89 | LANCL2 (0.70) | LANCL2HTR2BMEN1KMT2AHRH4 | |
| SCHEMBL23561760 | 0.88 | LANCL2 (0.63) | LANCL2HTR2ANPC1RAB9AHPGD | |
| SCHEMBL23561752 | 0.87 | LANCL2 (0.57) | LANCL2HTR2ANPC1RAB9AHPGD | |
| Omilancor SCHEMBL17706588 | 0.87 | LANCL2 (1.00) | LANCL2NPC1RAB9AHPGDALDH1A1 | |
| Omilancor SCHEMBL29349469 | 0.87 | LANCL2 (1.00) | LANCL2NPC1RAB9AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163017-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12145920-B2 | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same | NIMMUNE BIOPHARMA, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220274950-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2022-09-01 | — | — | US | disclosed |
| US-11377437-B2 | Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same | LANDOS BIOPHARMA, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377437-B2 | Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same | LANDOS BIOPHARMA, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-3927427-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20210355101-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210355101-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-11117881-B2 | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same | LANDOS BIOPHARMA, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117881-B2 | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same | LANDOS BIOPHARMA, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210188800-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188800-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| WO-2021127472-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163017-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LCP2, LANCL2, SSB | LANCL2 2/4885HTR2A 3535/4885NPC1 932/4885 |
| US-11377437-B2 | Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same | LCP2, LANCL2, SSB | LANCL2 2/4885HTR2A 3535/4885NPC1 932/4885 |
| US-20210355101-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LCP2, LANCL2, SSB | LANCL2 2/4885HTR2A 3535/4885NPC1 932/4885 |
| US-12145920-B2 | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same | LCP2, LANCL2, SSB | LANCL2 2/4885HTR2A 3535/4885NPC1 932/4885 |
| US-20210188800-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LCP2, LANCL2, SSB | LANCL2 2/4885HTR2A 3535/4885NPC1 932/4885 |
| US-11117881-B2 | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same | LCP2, LANCL2, SSB | LANCL2 2/4885HTR2A 3535/4885NPC1 932/4885 |
| US-20220274950-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LCP2, LANCL2, SSB | LANCL2 2/4885HTR2A 3535/4885NPC1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.